AK Burnett
About
In The Last Decade
AK Burnett
15 papers receiving 447 citations
Peers
Comparison fields: 5 of 58
- Hematology 346
- Genetics 204
- Nutrition and Dietetics 170
- Public Health, Environmental and Occupational Health 77
- Molecular Biology 64
Countries citing papers authored by AK Burnett
This map shows the geographic impact of AK Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by AK Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites AK Burnett more than expected).
Fields of papers citing papers by AK Burnett
This network shows the impact of papers produced by AK Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by AK Burnett. The network helps show where AK Burnett may publish in the future.
Co-authorship network of co-authors of AK Burnett
This figure shows the co-authorship network connecting the top 25 collaborators of AK Burnett. A scholar is included among the top collaborators of AK Burnett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with AK Burnett. AK Burnett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials | 29 |
| 2 | 1 | |
| 3 | 0 | |
| 4 | 8 | |
| 5 | Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials. | 2 |
| 6 | 70 | |
| 7 | A simple genetic test identifies 90% of UK patients with haemochromatosis | 179 |
| 8 | 67 | |
| 9 | 10 | |
| 10 | A PHASE-III RANDOMIZED PLACEBO-CONTROLED STUDY IN 315 PEDIATRIC AND ADULT AUTOLOGOUS OR ALLOGENEIC BONE-MARROW TRANSPLANTATION WITH LENOGRASTIM-5 UG/KG/DAY (GLYCOSYLATED RHU-G-CSF) | 4 |
| 11 | Amplification and sequencing of genomic breakpoints located within the M-bcr region by Vectorette-mediated polymerase chain reaction. | 11 |
| 12 | Mapping of breakpoints, and relationship to BCR-ABL RNA expression, in Philadelphia-chromosome-positive chronic myeloid leukaemia patients with a breakpoint around exon 14 (b3) of the BCR gene. | 24 |
| 13 | Toxoplasmosis after BMT for CML. | 10 |
| 14 | Absence of bcr rearrangement and bcr/abl RNA in a patient with a 31-year survival of CML. | 6 |
| 15 | Autograft to eliminate minimal residual disease in AML in first remission--update on the Glasgow experience. | 2 |
| 16 | Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. | 46 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.